Business & regional news

Now supported with effectiveness evidence, Medtronic DBS is the first and only U.S. FDA approved system to treat Dystonia symptoms

The pivotal Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial demonstrates global clinical effectiveness, long-term safety, and patient preference

Minimally invasive laser technology now with enhanced capital system improvements, offering new user interface, workflow efficiencies, and upgrade capabilities

Study shows 67% mean reduction in Low-back Visual Analog Scale (VAS) pain score at 12 months; 87% of subjects had meaningful improvements in three or more quality of life (QoL) domains

Data to be presented at the North American Neuromodulation Society (NANS) Annual Meeting 2025; In all, Medtronic to highlight 22 poster and oral scientific data presentations

ADAPT-PD trial methods and preliminary data published in npj Parkinson’s disease

New MRI labeling extends active scan time for Medtronic DBS systems

First ever FDA approval provides more options to meet patients’ personalized needs, including those with Parkinson’s disease

Deal expands Pain Interventions portfolio, now offering both unipedicular and bipedicular vertebral augmentation solutions

Doubled probe count enables multi-level spine tumor ablations for increased flexibility and efficiency Medtronic plc, a global leader in healthcare technology, today announced that it has received...